A. H. Sparre‐Ulrich

发表

Chemokine receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database

A. Mantovani, M. Rosenkilde, K. Matsushima, 2020 .

International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors

A. Mantovani, K. Matsushima, M. Thelen, 2014, Pharmacological Reviews.

Chemokine receptors in GtoPdb v.2023.1 Chemokine receptors in GtoPdb v.2023.1

A. Mantovani, K. Matsushima, M. Thelen, 2023 .

Loss of Function Glucose-Dependent Insulinotropic Polypeptide Receptor Variants Are Associated With Alterations in BMI, Bone Strength and Cardiovascular Outcomes

N. Grarup, M. Rosenkilde, A. Hauser, 2021, Frontiers in Cell and Developmental Biology.

Human GIP(3‐30)NH2 inhibits G protein‐dependent as well as G protein‐independent signaling and is selective for the GIP receptor with high‐affinity binding to primate but not rodent GIP receptors

M. Rosenkilde, B. Hartmann, A. Inoue, 2018, Biochemical pharmacology.

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

J. Holst, M. Rosenkilde, M. Christensen, 2018, Diabetologia.

The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor

J. Holst, J. Bülow, M. Rosenkilde, 2017, Diabetes.

N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor

J. Holst, M. Rosenkilde, B. Hartmann, 2016, British journal of pharmacology.

GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP‐mediated insulin, glucagon, and somatostatin release

M. Rosenkilde, A. H. Sparre-Ulrich, B. Svendsen, 2017, Biochemical pharmacology.

Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

J. Holst, M. Rosenkilde, B. Hartmann, 2015, British journal of pharmacology.

AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys

S. J. Sanni, M. Jensen, J. J. Holst, 2024, Molecular metabolism.

Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes

J. Holst, B. Hartmann, T. Vilsbøll, 2015, International Journal of Obesity.

Acute concomitant glucose‐dependent insulinotropic polypeptide receptor antagonism during glucagon‐like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

J. Holst, M. Rosenkilde, M. Christensen, 2022, Diabetes, obesity & metabolism.

Extracellular Disulfide Bridges Serve Different Purposes in Two Homologous Chemokine Receptors, CCR1 and CCR5

M. Rosenkilde, A. H. Sparre-Ulrich, T. Ulven, 2013, Molecular Pharmacology.